MedTrace Logo

Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control

NCT01626248 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 164

Last updated 2013-06-14

No results posted yet for this study

Summary

The purpose of the study is to research the association between receiving Tysabri® (natalizumab), interferon beta-1a, glatiramer acetate or not having any treatment for your MS and how it may or may not impact certain white blood cells and other immunological markers. This information may be useful in identifying risk factors in developing progressive multifocal leukoencephalopathy (PML). It does appear that the risk increases with the total number of natalizumab infusions. Patients who have not yet started a disease modifying therapy or who have been on one other than natalizumab are needed as controls to see how these biomarkers change.

Patients at various stages of natalizumab treatment as well as natalizumab naïve are needed to allow for analysis of the change in potential markers over time.

Conditions

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • Elan Pharmaceuticals

    collaborator INDUSTRY

  • John F. Foley, MD

    lead OTHER

Principal Investigators

  • John F Foley, MD · Rocky Mountain MS Research Group, LLC

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-03-31
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01626248 on ClinicalTrials.gov